Aardvark prices $94.2m IPO to fund development of Prader-Willi syndrome drug
Aardvark’s lead candidate ARD-101 is being investigated in a Phase III study for hyperphagia in Prader-Willi syndrome.
Aardvark’s lead candidate ARD-101 is being investigated in a Phase III study for hyperphagia in Prader-Willi syndrome.
What's Your Reaction?
